Evaluation of the Relationship between Fecal/ Serum Levels of Infliximab and Clinical Response to Treatment of IBD patients: A Cross-sectional Study
Foroogh Alborzi, Hesam Aldin Varpaei, Nasser Ebrahimi Daryani, Keyvan Rezvan & Sara Rafiee Sevyeri · Asian Journal of Research and Reports in Gastroenterology · 2022
Background: Inflammatory bowel disease (IBD) includes two major disorders: ulcerative colitis (UC) and Crohn's disease (CD). Infliximab is a monoclonal antibody that targets tumor necrosis factor (TNF) and is used to treat UC and CD. The aim of this study was to...
Open access
Research Article